Describe rifampicin with its mechanism, uses, adverse effects and interactions.
Pharmacology
Rifampicin inhibits DNA-dependent RNA polymerase by binding its beta subunit, blocking transcription. It is bactericidal and acts on both dividing and semi-dormant organisms.
- Its sterilising activity against persisters is why modern short-course chemotherapy is possible — rifampicin reduced treatment from 18 months to 6
- Well absorbed orally (better on an empty stomach); excellent tissue and CSF penetration; excreted chiefly in bile with enterohepatic circulation
- Resistance arises from a single-step mutation in the rpoB gene — which is why it must never be used alone, and why molecular detection of rifampicin resistance (CBNAAT) is such a useful proxy for MDR-TB
Uses
- Tuberculosis — in every regimen for drug-sensitive disease
- Leprosy — the most potent bactericidal antileprotic; a single monthly supervised dose is a component of multidrug therapy
- Meningococcal carriage and contact prophylaxis
- Staphylococcal infection of prosthetic material — rifampicin penetrates biofilm well and is added to another agent (never alone)
- Brucellosis, Legionella, and MAC infection
- Pruritus of cholestasis, an unrelated use exploiting enzyme induction
Adverse Effects
| Effect | Details |
|---|---|
| Orange-red discolouration | Of urine, sweat, tears, sputum and saliva — entirely harmless, but alarming if not forewarned, and it permanently stains soft contact lenses. Failure to warn is a recognised cause of treatment default |
| Hepatotoxicity | Cholestatic pattern; potentiated by isoniazid and pyrazinamide; also causes a harmless unconjugated hyperbilirubinaemia early by competing for hepatic uptake |
| Intermittent-dose ("flu") syndrome | With intermittent or interrupted therapy — fever, chills, myalgia, headache; and less commonly thrombocytopenia, haemolytic anaemia, acute interstitial nephritis and shock, all immunologically mediated. These require permanent withdrawal |
| Gastrointestinal | Nausea, anorexia, abdominal pain |
| Cutaneous | Rash, pruritus, flushing |
CLINICAL PEARL
Rifampicin is the most powerful enzyme inducer in common clinical use, and this causes more problems than its toxicity does. It induces CYP3A4 and P-glycoprotein within days, and the consequences include unplanned pregnancy from oral contraceptive failure, loss of anticoagulation, transplant rejection from reduced ciclosporin levels, and antiretroviral failure. In India, where rifampicin is prescribed to millions, this single interaction profile deserves as much attention as any adverse effect.
Interactions
- Drugs whose levels fall substantially — oral contraceptives, warfarin, corticosteroids, ciclosporin and tacrolimus, oral hypoglycaemics, digoxin, phenytoin, theophylline, azole antifungals, and most antiretrovirals
- Alternative contraception must be advised for the duration and for several weeks afterwards
- Protease inhibitors cannot generally be given with rifampicin; rifabutin is substituted, being a much weaker inducer, and the dolutegravir dose is doubled
- Induction persists for 1 to 2 weeks after stopping, so doses of the affected drugs must be readjusted downward at that point — a step often forgotten, with bleeding on warfarin as a result
Applied Aspects
- Warn about orange secretions and contact lenses before the first dose
- Review every other drug the patient takes when starting or stopping rifampicin, and again two weeks after stopping
- Never give rifampicin alone for any mycobacterial infection; single-step resistance follows within weeks
- CBNAAT detects rifampicin resistance in under 2 hours, and a positive result is treated as MDR-TB until proved otherwise — the single most useful diagnostic advance in Indian tuberculosis practice
- Take it on an empty stomach, an hour before food, since absorption is reduced by a meal
- Monitor liver function where risk factors exist, and counsel on the symptoms that require immediate attention
All questions in Antimicrobials: TB, Fungal, Viral & Antiparasitic
- Q1Classify antitubercular drugs. Describe the first-line drugs with their mechanisms and adverse effects, the standard regimens and drug-resistant tuberculosis. ★
- Q2Classify antimalarial drugs by stage of action. Describe chloroquine, the artemisinins and the other agents. ★
- Q3Classify antifungal drugs. Describe amphotericin B and the azoles with their uses and adverse effects. ★
- Q4Describe the antiviral drugs and the principles of antiretroviral therapy. ★
- Q5Classify anthelmintic drugs. Describe the antiamoebic drugs and the treatment of visceral leishmaniasis. ★
- SN1Describe isoniazid with its mechanism, acetylation polymorphism, adverse effects and uses. ★
- SN2Describe rifampicin with its mechanism, uses, adverse effects and interactions. ★
- SN3Describe the antileprotic drugs and WHO multidrug therapy. Add a note on lepra reactions. ★
- SN4Describe chloroquine with its mechanism, uses, adverse effects and resistance. ★
- SN5Explain the rationale for artemisinin-based combination therapy and describe the regimens used in India. ★
- SN6Describe amphotericin B with its mechanism, formulations, uses and toxicity. ★
- SN7Describe the drugs used in visceral leishmaniasis and the basis of the elimination programme in India.